The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis
Open accessAbstract
Importance: It is unclear whether female carriers of the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive impairment (MCI) and APOE has not been established. Objective: To determine how sex and APOE genotype affect the risks for developing MCI and AD. Data Sources: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants. Study Selection: Non-Hispanic white individuals with clinical diagnostic and APOE genotype data. Data Extraction and Synthesis: Homogeneous data sets were pooled in case-control analyses, and logistic regression models were used to compute risks. Main Outcomes and Measures: Age-adjusted odds ratios (ORs) and 95% confidence intervals for developing MCI and AD were calculated for men and women across APOE genotypes. Results: Participants were men and women between ages 55 and 85 years. Across data sets most participants were white, and for many participants, racial/ethnic information was either not collected or not known. Men (OR, 3.09; 95% CI, 2.79-3.42) and women (OR, 3.31; CI, 3.03-3.61) with the APOE ε3/ε4 genotype from ages 55 to 85 years did not show a difference in AD risk; however, women had an increased risk compared with men between the ages of 65 and 75 years (women, OR, 4.37; 95% CI, 3.82-5.00; men, OR, 3.14; 95% CI, 2.68-3.67; P = .002). Men with APOE ε3/ε4 had an increased risk of AD compared with men with APOE ε3/ε3. The APOE ε2/ε3 genotype conferred a protective effect on women (OR, 0.51; 95% CI, 0.43-0.61) decreasing their risk of AD more (P value = .01) than men (OR, 0.71; 95% CI, 0.60-0.85). There was no difference between men with APOE ε3/ε4 (OR, 1.55; 95% CI, 1.36-1.76) and women (OR, 1.60; 95% CI, 1.43-1.81) in their risk of developing MCI between the ages of 55 and 85 years, but women had an increased risk between 55 and 70 years (women, OR, 1.43; 95% CI, 1.19-1.73; men, OR, 1.07; 95% CI, 0.87-1.30; P = .05). There were no significant differences between men and women in their risks for converting from MCI to AD between the ages of 55 and 85 years. Individuals with APOE ε4/ε4 showed increased risks vs individuals with ε3/ε4, but no significant differences between men and women with ε4/ε4 were seen. Conclusions and Relevance: Contrary to long-standing views, men and women with the APOE ε3/ε4 genotype have nearly the same odds of developing AD from age 55 to 85 years, but women have an increased risk at younger ages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“APOE-e4 was related to higher Alzheimer's risk in women than men between ages 55 to 70”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Carrying one APOE4 allele increases the risk of AD by 3–4 times, and carrying two alleles increases the risk by 9–15 times.168”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [168]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That is, APOE‐e4 was related to higher Alzheimer's risk in women than men between ages 55 and 70, when APOE is thought to exert its largest effects.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent meta-analysis found no difference between men and women in the association between APOE-e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [288]
The cited source says what the claim attributes to it.
In the citing paper
“APOE is differentially associated with AD risk across populations [16]”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Women are more vulnerable to effects of APOE4 on memory decline [45] as well as risk for AD dementia [16] and neuropathology [46], and more limited data suggest that APOE2 also confers greater protection against AD risk for women than men [16].”
From Effects of APOE2 and APOE4 on brain microstructure in older adults: modification by age, sex, and cognitive status (2024) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“However, a meta‐analysis found no difference between men and women in the association between APOE‐e4 and Alzheimer's dementia overall, although age played an interesting interactive role.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [314]
The cited source says what the claim attributes to it.
In the citing paper
“Epidemiologic studies show sex differences in clinical risk are largely discernable within the context of APOE ε4,11,42,43 particularly between the ages of 65 to 75 years compared with APOE ε4 clinically normal male carriers.44”
From Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults (2019) · cites this paper as [44]
In the citing paper
“Attempts to quantify the duration of AD should be age-specific, because age imposes the greatest risk for both dementia and mortality, and take into account APOE genotype, sex, and cerebrospinal fluid (CSF) tau levels [4, 6, 10-12].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
The projected effect of risk factor reduction on Alzheimer's disease prevalence
Barnes, D. E., & Yaffe, K. S. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70072-2 · Cited by 2,846
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857
Mild cognitive impairment: a concept in evolution
Petersen, R. C., Caracciolo, B., Brayne, C., Gauthier, S., Jelic, V., & Fratiglioni, L. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12190 · Cited by 1,694
The normal menopause transition
McKinlay, S. M., Brambilla, D. J., & Posner, J. G. (1992) · Maturitas · doi:10.1016/0378-5122(92)90003-m · Cited by 1,112
Sex Differences in Stroke Epidemiology
Appelros, P., Stegmayr, B., & Terént, A. (2009) · Stroke · doi:10.1161/strokeaha.108.540781 · Cited by 1,076
Natural history of mild cognitive impairment in older persons
Bennett, D. A., Wilson, R. S., Schneider, J. A., Evans, D. A., Beckett, L. A., Aggarwal, N. T., Barnes, L. L., Fox, J. H., & Bach, J. (2002) · Neurology · doi:10.1212/wnl.59.2.198 · Cited by 1,037
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
Ellis, K. A., Bush, A. I., Darby, D., Fazio, D. D., Foster, J. K., Hudson, P. J., Lautenschlager, N. T., Lenzo, N. P., Martins, R. N., Maruff, P. T., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 1,005
The National Alzheimer's Coordinating Center (NACC) Database: The Uniform Data Set
Beekly, D. L., Ramos, E. M., Lee, W. W., Deitrich, W. D., Jacka, M. E., Wu, J., Hubbard, J. L., Koepsell, T. D., Morris, J. C., & Kukull, W. A. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318142774e · Cited by 907
Self-citationSex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
Dementia and Alzheimer Disease Incidence: A Prospective Cohort Study
Kukull, W. A., Higdon, R., Bowen, J. D., McCormick, W. C., Teri, L., Schellenberg, G. D., van Belle, G., Jolley, L., & Larson, E. B. (2002) · Archives of Neurology · doi:10.1001/archneur.59.11.1737 · Cited by 806
Self-citationPetersen, R. C. (1995) · JAMA · doi:10.1001/jama.1995.03520400044042 · Cited by 783
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Weiner, M. W., Aisen, P. S. S., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Shaw, L. M. J., Saykin, A. J., Morris, J. C., Cairns, N. J., Beckett, L. A., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.007 · Cited by 613
Self-citationApoE genotype accounts for the vast majority of AD risk and AD pathology
Raber, J., Huang, Y., & Ashford, J. W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.023 · Cited by 599
AN APPROACH TO LONGITUDINAL STUDIES IN A COMMUNITY: THE FRAMINGHAM STUDY
Dawber, T. R., Kannel, W. B., & Lyell, L. P. (1963) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1963.tb13299.x · Cited by 561
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537
Gender and incidence of dementia in the Framingham Heart Study from mid‐adult life
Chêne, G., Beiser, A., Au, R., Preis, S. R., Wolf, P. A., Dufouil, C., & Seshadri, S. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.10.005 · Cited by 499
Self-citationGAB2 Alleles Modify Alzheimer's Risk in APOE ɛ4 Carriers
Reiman, E. M., Webster, J. A., Myers, A. J., Hardy, J., Dunckley, T., Zismann, V. L., Joshipura, K. D., Pearson, J. V., Hu-Lince, D., Huentelman, M. J., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.05.022 · Cited by 487
Self-citationLopez, O. L., Jagust, W. J., Dulberg, C., Becker, J. T., DeKosky, S. T., Fitzpatrick, A., Breitner, J., Lyketsos, C., Jones, B., Kawas, C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.10.1394 · Cited by 477
The Rush Memory and Aging Project: Study Design and Baseline Characteristics of the Study Cohort
Bennett, D. A., Schneider, J. A., Buchman, A. S., de Leon, C. F. M., Bienias, J. L., & Wilson, R. S. (2005) · Neuroepidemiology · doi:10.1159/000087446 · Cited by 413
Slooter, A. J. C., Cruts, M., Kalmijn, S., Hofman, A., Breteler, M. M. B., Van Broeckhoven, C., & van Duijn, C. M. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.964 · Cited by 399
APOE -ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
Breitner, J. C. S., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C., Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., Skoog, I., et al. (1999) · Neurology · doi:10.1212/wnl.53.2.321 · Cited by 397
Risk of Dementia Among White and African American Relatives of Patients With Alzheimer Disease
Green, R. C. (2002) · JAMA · doi:10.1001/jama.287.3.329 · Cited by 391
Loy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60630-3 · Cited by 342
Is the Risk of Developing Alzheimer's Disease Greater for Women than for Men?
Hebert, L. E., Scherr, P. A., McCann, J. J., Beckett, L. A., & Evans, D. A. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.2.132 · Cited by 331
Genetic Control of Human Brain Transcript Expression in Alzheimer Disease
Webster, J. A., Gibbs, J. R., Clarke, J., Ray, M., Zhang, W., Holmans, P., Rohrer, K., Zhao, A., Marlowe, L., Kaleem, M., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.03.011 · Cited by 304
Lautenschlager, N. T., Cupples, L. A., Rao, V. S., Auerbach, S. A., Becker, R., Burke, J., Chui, H., Duara, R., Foley, E. J., Glatt, S. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.641 · Cited by 298
Self-citationTervo, S., Kivipelto, M., Hänninen, T., Vanhanen, M., Hallikainen, M., Mannermaa, A., & Soininen, H. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000076356 · Cited by 298
Risk factors for late‐ onset Alzheimer's disease: A population‐ based, case‐control study
Fratiglioni, L., Ahlbom, A., Viitanen, M., & Winblad, B. (1993) · Annals of Neurology · doi:10.1002/ana.410330306 · Cited by 298
Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer’s disease
Carrasquillo, M. M., Zou, F., Pankratz, V. S., Wilcox, S. L., Ma, L., Walker, L. P., Younkin, S. G., Younkin, C. S., Younkin, L. H., Bisceglio, G. D., et al. (2009) · Nature Genetics · doi:10.1038/ng.305 · Cited by 296
Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia
DeCarli, C. S., Mungas, D., Harvey, D., Reed, B., Weiner, M. W., Chui, H. C., & Jagust, W. J. (2004) · Neurology · doi:10.1212/01.wnl.0000130531.90205.ef · Cited by 276
Genome-wide Association Study Implicates a Chromosome 12 Risk Locus for Late-Onset Alzheimer Disease
Beecham, G. W., Martin, E. R., Li, Y.-J., Slifer, M. A., Gilbert, J. R., Haines, J. L., & Pericak-Vance, M. A. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.008 · Cited by 260
Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., Bird, T. D., Yu, C. E., Wijsman, E. M., Heston, L. L., Litt, M. J., et al. (1996) · PubMed Central · Cited by 248
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
Sager, M. A., Hermann, B. P., & Rue, A. L. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281882 · Cited by 224
Alzheimer's Disease, Apolipoprotein E4, and Gender
Payami, H. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510410028015 · Cited by 190
Suri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183
Risk factors for transitions from normal to mild cognitive impairment and dementia
Kryscio, R. J., Schmitt, F. A., Salazar-Uribe, J. C., Mendiondo, M. S., & Markesbery, W. R. (2006) · Neurology · doi:10.1212/01.wnl.0000203264.71880.45 · Cited by 173
A gender difference in the association between APOE genotype and age-related cognitive decline
Mortensen, E. L., & Høgh, P. (2001) · Neurology · doi:10.1212/wnl.57.1.89 · Cited by 171
Predictive value of APOE- 4 allele for progression from MCI to AD-type dementia: a meta-analysis
Elias-Sonnenschein, L. S., Viechtbauer, W., Ramakers, I. H. G. B., Verhey, F. R. J., & Visser, P. J. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.231555 · Cited by 154
Caselli, R. J., Reiman, E. M., Locke, D. E. C., Hutton, M. L., Hentz, J. G., Hoffman‐Snyder, C., Woodruff, B. K., Alexander, G. E., & Osborne, D. (2007) · Archives of Neurology · doi:10.1001/archneur.64.9.1306 · Cited by 153
Beydoun, M. A., Boueiz, A., Abougergi, M. S., Kitner-Triolo, M. H., Beydoun, H. A., Resnick, S. M., O'Brien, R., & Zonderman, A. B. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.017 · Cited by 139
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.
Bickeböller, H., Campion, D., Brice, A., Amouyel, P., Hannequin, D., Didierjean, O., Penet, C., Martin, C., Pérez‐Tur, J., Michon, A., et al. (1997) · Europe PMC (PubMed Central) · Cited by 135
Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study
Lee, J. H. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1518 · Cited by 126
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Devanand, D. P., Pelton, G. H., Zamora, D., Liu, X., Tabert, M. H., Goodkind, M. S., Scarmeas, N., Braun, I. M., Stern, Y., & Mayeux, R. P. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.975 · Cited by 122
Characteristics of Nonresponders in A Community Survey of the Elderly
Norton, M. C., Breitner, J. C. S., Welsh-Bohmer, K. A., & Wyse, B. W. (1994) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1994.tb06506.x · Cited by 117
Mayeux, R., Sano, M., Chen, J., Tatemichi, T., & Stern, Y. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530150037014 · Cited by 117
On Heterogeneity Tests Based on Efficient Scores
Tarone, R. E. (1985) · Biometrika · doi:10.1093/biomet/72.1.91 · Cited by 105
Farrer, L. A., Cupples, L. A., van Duijn, C. M., Kurz, A., Zimmer, R., Müller, U., Green, R. C., Clarke, V., Shoffner, J. M., Wallace, D. C., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380515 · Cited by 100
Self-citationAggarwal, N. T., Wilson, R. S., Beck, T. L., Bienias, J. L., Berry‐Kravis, E., & Bennett, D. A. (2005) · Neurocase · doi:10.1080/13554790490903038 · Cited by 88
Boyle, P. A., Buchman, A. S., Wilson, R. S., Kelly, J. F., & Bennett, D. A. (2009) · Neuroepidemiology · doi:10.1159/000256662 · Cited by 88
Markers of Alzheimer's disease in a population attending a memory clinic
Frisoni, G. B., Prestia, A., Zanetti, O. O., Galluzzi, S., Romano, M., Cotelli, M., Gennarelli, M., Binetti, G. G., Bocchio‐Chiavetto, L., Paghera, B., et al. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.1235 · Cited by 84
Self-citationBoada, M., Tárraga, L., Hernández, I., Valero, S., Alegret, M., Ruiz, A., López, O. L., & Becker, J. T. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.03.006 · Cited by 79
Self-citationAssociation of CLU and PICALM variants with Alzheimer's disease
Kamboh, M. I., Minster, R. L., Demirci, F. Y., Ganguli, M., DeKosky, S. T., López, O. L., & Barmada, M. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.015 · Cited by 77
Anatomical MRI and DTI in the Diagnosis of Alzheimer's Disease: A European Multicenter Study
Teipel, S. J., the EDSD study group, Wegrzyn, M., Meindl, T., Frisoni, G., Bokde, A. L. W., Fellgiebel, A., Filippi, M., Hampel, H., Klöppel, S., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-112118 · Cited by 76
Self-citationGalluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Antelmi, L., Bagnoli, C., David Bartrés-faz, A., Cordone, S., Didic, M., Farotti, L., et al. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12482 · Cited by 76
Self-citationTsuang, D., Kukull, W., Sheppard, L., Barnhart, R. L., Peskind, E., Edland, S. D., Schellenberg, G., Raskind, M., & Larson, E. B. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01836.x · Cited by 69
Self-citationBarabash, A., Marcos, A., Ancín, I., Vázquez-Álvarez, B., de Ugarte, C., Gil, P., Fernández, C., Encinas, M., López-Ibor, J. J., & Cabranes, J. A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.003 · Cited by 66
The Global Alzheimer's Association Interactive Network
Toga, A. W., Neu, S., Bhatt, P. R., Crawford, K. L., & Ashish, N. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1896 · Cited by 65
Self-citationApolipoprotein E ϵ4 Allele and Familial Aggregation of Alzheimer Disease
Martinez, M. M., Campion, D., Brice, A., Hannequin, D., Dubois, B., Didierjean, O., Michon, A., Thomas-Antérion, C., Puel, M., Frébourg, T., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.6.810 · Cited by 63
Molero, A. E., Pino‐Ramírez, G., & Maestre, G. E. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01911-5 · Cited by 57
Lehmann, D. J. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.077818 · Cited by 52
Brainerd, C. J., Reyna, V. F., Petersen, R. C., Smith, G. E., Kenney, A. E., Gross, C. J., Taub, E. S., Plassman, B. L., & Fisher, G. G. (2013) · Neuropsychology · doi:10.1037/a0030855 · Cited by 38
Development of a unified clinical trial database for Alzheimer's disease
Neville, J., Kopko, S., Broadbent, S., Avilés, E., Stafford, R., Solinsky, C. M., Bain, L. J., Cisneroz, M., Romero, K., Stephenson, D. T., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.005 · Cited by 37
Self-citationAccelerated Progression from Mild Cognitive Impairment to Dementia Among APOE ε4ε4 Carriers
Xu, W., Caracciolo, B., Wang, H., Santoni, G., Winblad, B. G., & Fratiglioni, L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121369 · Cited by 34
Galluzzi, S., Testa, C., Boccardi, M., Bresciani, L. C., Benussi, L., Ghidoni, R., Beltramello, A., Bonetti, M., Bono, G. G., Falini, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03324915 · Cited by 32
Self-citationSharing data in the global alzheimer's association interactive network
Neu, S., Crawford, K. L., & Toga, A. W. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.082 · Cited by 28
Self-citationThe Effect of MAPT H1 and APOE ε4 on Transition from Mild Cognitive Impairment to Dementia
Samaranch, L., Cervantes, S., Barabash, A., Alonso, Á., Cabranes, J. A., Lamet, I., Ancín, I., Lorenzo, E., Martínez‐Lage, P., Marcos, A., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101011 · Cited by 27
Gender effect on apolipoprotein E 84 allele-associated risk for sporadic Alzheimer's disease
Combarros, O., Leno, C., Oterino, A., Berciano, J., Fernández-Luna, J. L., Fernández‐Viadero, C., Peña, N., Miró, J. M., & Delgado‐Rodríguez, M. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00611.x · Cited by 20
P1‐061: Nia genetics of Alzheimer's disease data storage site (NIAGADS): 2015 update
Partch, A. B., Laufer, D., Valladares, O., Iodice, J., Greenfest‐Allen, E., Childress, D. M., Malamon, J. S., Gangadharan, P., Arnold, S. E., Stoeckert, C. J., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.258 · Cited by 2
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2022 Alzheimer's disease facts and figures
Anonymous (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12638 · Cited by 2,469
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Neu, S. C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K., Arneric, S. P., Redolfi, A., Orlandi, D., Frisoni, G. B., Au, R., Devine, S., Auerbach, S., Espinosa, A., Boada, M., Ruiz, A., Johnson, S. C., Koscik, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., & Toga, A. W.
- Affiliations
- University of Southern California (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Critical Path Institute (US)
- Coalition Against Major Disease, Critical Path Institute, Tucson, Arizona
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Geneva (CH)
- Boston University (US)
- Fundació ACE (ES)
- Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- University of Wisconsin–Madison (US)
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
- Corresponding author
- Toga, Arthur W.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-10-01
- Volume
- 74
- Issue
- 10
- Pages
- 1178
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC5759346
- OpenAlex
- W2745657465
- Cited by
- 674
- References
- 74
- Citations by year
- 2026: 74 · 2025: 81 · 2024: 74 · 2023: 93 · 2022: 78 · 2021: 96 · 2020: 69 · 2019: 67 · 2018: 37 · 2017: 3
- FWCI
- 39.51
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- JAMA Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000130, 5u01ag024904-10, n01hc25195-41-0-1, UL1TR001855)
- U.S. Food and Drug Administration (U18FD005320)
- National Institute on Aging (U01-AG-024904, P30AG010129, P30AG010133, P30AG028383, P30AG012300, P50AG005133, U01AG016976, P50AG005131, P50AG005138, P50AG016570, P30AG010124, P50AG016573, RF1AG027161, P50AG047366, P30AG008017, P30AG010161, R01AG033040, P30AG008051, P50AG008702, R01AG016495, P50AG033514, P30AG035982, P50AG005681, P50AG005142, P50AG047270, P30AG019610, P50AG005146, P01AG003991, RF1AG054617, P30AG013846, P50AG005136, P50AG005134, P30AG013854, P50AG025688, P50AG047266, R01AG008122, R01AG027161, U24AG041689, U19AG024904, P01AG026276, P50AG023501, P50AG016574)
- National Heart, Lung, and Blood Institute (N01-HC-025195)
- National Institute of Neurological Disorders and Stroke (R01NS017950)
- National Institute of Biomedical Imaging and Bioengineering (U54EB020406, P41EB015922)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- Alzheimer's disease, apolipoprotein E, APOE ε4, APOE ε2, sex differences, mild cognitive impairment, genetic risk factors
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Female, Humans, Male, Middle Aged, Risk Factors, Sex Characteristics, Logistic Models, Case-Control Studies, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
